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SUMMARY
AF10, a DOT1L cofactor, is required for H3K79 methylation and cooperates with DOT1L in 
leukemogenesis. However, the molecular mechanism by which AF10 regulates DOT1L-mediated 
H3K79 methylation is not clear. Here, we report that AF10 contains a “reader” domain that 
couples unmodified H3K27 recognition to H3K79 methylation. An AF10 region consisting of a 
PHD finger-Zn knuckle-PHD finger (PZP) folds into a single module that recognizes amino acids 
22-27 of H3, and this interaction is abrogated by H3K27 modification. Structural studies reveal 
that H3-binding triggers rearrangement of the PZP module to form an H3(22-27)-accommodating 
channel and the unmodified H3K27 side-chain is encased in a compact hydrogen bond acceptor-
lined cage. In cells, PZP recognition of H3 is required for H3K79 dimethylation, expression of 
DOT1L-target genes, and proliferation of DOT1L-addicted leukemic cells. Together, our results 
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The readout of histone post-translational modifications (PTMs) is crucial for understanding 
how chromatin dynamics influence the regulation of the genome (Taverna et al., 2007). To 
date, PHD finger domains represent the largest known class of reader domains that are 
sensitive to methyl-lysine (Musselman and Kutateladze, 2011). For example, there are 
dozens of PHD fingers that specifically bind to H3K4me3, (trimethylation of K4 on H3), 
which is a hallmark of active transcription. These proteins include the second PHD finger of 
the chromatin remodeler BPTF (Li et al., 2006; Wysocka et al., 2006), PHD fingers from the 
ING tumor suppressor families (Pena et al., 2006; Shi et al., 2006), the PHD finger of 
RAG2, an essential component of the RAG1/2 V(D)J recombinase (Matthews et al., 2007) 
and the PHD finger from the core transcriptional machinery protein TAF3 (Vermeulen et al., 
2007). Besides PHD fingers that recognize H3K4me3, a second class of PHD fingers first 
discovered on the chromatin regulator BHC80, bind to the very N-terminus of H3 tails and 
are repelled by methylation at H3K4 (Lan et al., 2007).
In the human genome, eleven proteins present in four families (JADE, BRPF, KDM4, and 
AF10/17) contain the chromatin-associated PHD finger-Zn knuckle-PHD finger (PZP) 
module (Figure 1A and S1A; (Klein et al., 2014)). The first PHD finger of the PZP domain 
within the JADE (JADE1/2/3) and BRPF (BRPF1/2/3) families behaves similar to BHC80 
to regulate histone acetyltransferase (HAT) complexes (Lalonde et al., 2013; Saksouk et al., 
2009). Notably, the second PHD finger cooperates with the first PHD finger to mediate 
nucleosome binding through a mechanism that is yet to be elucidated (Klein et al., 2014; 
Lalonde et al., 2013).
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AF10 and AF17 are both subunits of the multimeric DOT1L complex that mediates H3K79 
methylation (Mohan et al., 2010). Besides the PZP domain, both proteins contain an 
octapeptide motif and leucine zipper (OM-LZ) domain (see schematic, Figure 1A) that 
directly binds to DOT1L. In addition, the AF10 and AF17 genes are both involved in 
recurrent chromosomal translocations in human leukemia, suggesting a key role for these 
proteins in leukemogenesis (Moore et al., 2005; Prasad et al., 1994; Suzukawa et al., 2005). 
A common theme amongst AF10-translocated leukemias is the aberrant expression of the 
homebox (HOX) gene cluster, which is implicated in the propagation of the leukemic state 
(Dik et al., 2005; Okada et al., 2006). Recent studies demonstrated that continued expression 
of the leukemogenic HOX genes – specifically at the HOXA cluster – is dependent on AF10 
(Chen et al., 2013; Deshpande et al., 2014; DiMartino et al., 2002). Importantly, the 
dependence of HOXA gene expression on AF10 is not limited to AF10-translocated 
leukemias, suggesting important functions for the intact protein (Deshpande et al., 2014). 
Thus, AF10 is a potential candidate for therapeutic intervention in leukemia and perhaps 
other malignancies that are driven by abnormal HOX gene activation.
Here, we characterize the histone-binding activities of the AF10 and AF17 PZP domains. 
We find that in contrast to other PZP domains or any previously characterized reader 
domain, the AF10 and AF17 PZP domains recognize a region of H3 that spans amino acids 
22 to 27. This interaction with H3 occurs both in the context of peptides and nucleosomes 
and is inhibited by covalent modification, notably methylation at H3K27. We solved the 
crystal structure of the AF10 PZP domain bound to H3 peptide, which revealed that all three 
motifs of the PZP domain cooperate as a unique compact scaffold to mediate H3 
recognition. We established a cellular complementation system to functionally investigate 
the structure and demonstrated that maintenance of H3K79me2 at physiologic levels in cells 
is dependent upon the ability of AF10 to bind unmodified H3K27. At DOT1L gene targets, 
the AF10PZP-H3 interaction is needed for AF10 occupancy and enrichment of H3K79me2. 
The interaction is also required for expression of DOT1L-target genes and for full 
proliferative capacity of a DOT1L-dependent leukemia cell line. Thus, our study identifies a 
function for the unmodified state of H3K27 in regulating the evolutionarily conserved and 
canonical H3K79 methylation mark.
RESULTS
The PZP Domains of AF10 and AF17 Bind Nucleosomes via Amino Acids 15-34 of H3
To test whether the largely identical PZP domains of AF10 and AF17 (AF10PZP and 
AF17PZP, respectively; 91% identity, see sequence alignment in Figure S1A), like the PZP 
domains of the JADE and BRPF proteins, interact with nucleosomes, we performed pull-
down assays with recombinant PZP domains and recombinant nucleosomes (rNuc) 
containing biotinylated DNA (Lalonde et al., 2013). As shown in Figure 1B, AF10PZP and 
AF17PZP as well as the positive control JADE1PZP bound rNuc, whereas the GST control 
did not. Moreover, like the JADE1 PZP domain, the N-terminal tail of H3 is necessary for 
the interaction of AF10PZP and AF17PZP with nucleosomes (Figure 1C). To determine if 
there was a specific region within the H3 N-terminus sufficient for the interaction, pull-
down assays were performed using a series of biotinylated peptides spanning the tail region. 
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In contrast to JADE1PZP, which bound as expected to a peptide spanning amino acids 1-21 
(H31-21; the very N-terminus of H3) (Saksouk et al., 2009), both AF10PZP and AF17PZP did 
not bind the H31-21 peptide but rather bound to a peptide spanning amino acids 15-34 
(H315-34; Figure 1D). The AF10PZP, in addition to being sufficient, is also necessary for 
full-length AF10 to bind H315-34 (Figure S1B). Finally, all three domains of the PZP module 
(see schematic Figure 1A) are necessary for binding to H315-34 as individual domains within 
the PZP of AF10 and AF17 as well as PHD1-Zn knuckle and Zn knuckle-PHD2 
polypeptides did not bind to any of the peptides or to nucleosomes (data not shown). We 
conclude that in the context of histone binding, AF10PZP and AF17PZP each behave as a 
single functional unit that binds to a region of H3 that spans amino acids 15-34.
AF10PZP and AF17PZP Binding to H3 is Repelled by Methylation and Acetylation at K27
H3K27 methylation is a canonical and biologically important modification present within 
the H315-34 peptide (Vizan et al., 2014). As many PHD fingers function as highly sensitive 
“readers” of the methylation status at H3K4, we asked if the PHD-finger-containing 
AF10PZP and AF17PZP domains have a similar relationship to the methylation status at 
H3K27. Notably, in contrast to the H3K27me-binding chromodomain of CBX7 (Yap et al., 
2010), the interaction of AF10PZP and AF17PZP to the H315-34 peptide was abolished by 
mono-, di-, and tri-methylation at K27 (Figure 1E). Quantitation of the interaction by 
isothermal titration calorimetry (ITC) demonstrated that AF10PZP bound H315-34 peptides 
with a Kd of ~5 μM and the binding could no longer be detected upon addition of a single 
methyl moiety, as well as di- and tri-methylation, at K27 (Figure 1F and S1C). Finally, 
H3K27 is also acetylated in cells, and this modification, like methylation, disrupted 
recognition of H3 by AF10PZP and AF17PZP (Figure 1G; data not shown).
To address the role of H3K27 modification in the context of nucleosome recognition, we 
used methyl lysine analog chemistry (Simon et al., 2007) to install tri-methylation at either 
lysine 4 (H3KC4me3) or lysine 27 (H3KC27me3) on rNucs. Consistent with the results 
obtained when using peptides, AF10PZP and AF17PZP bound to control and H3KC4me3 
rNucs but not to H3KC27me3 nucleosomes (Figure 1H). Thus, we conclude that nucleosome 
recognition by the PZP domains of AF10 and AF17 is antagonized by methylation at lysine 
27.
Structure of AF10PZP in the Free State
In order to understand the molecular basis of AF10PZP-H3K27 interaction, we first 
determined the structure of AF10PZP in the apo-form. We focused on AF10, as this protein 
but not AF17 has been shown to regulate H3K79 methylation (Mohan et al., 2010). The 
structure of free AF10PZP was solved at 1.6 Å resolution (x-ray statistics listed in Table 1). 
The protein adopts a unique fold composed of PHD finger 1 (in blue) coordinated by Zn1 
and Zn2, a Zn-knuckle (in green) coordinated by Zn3, and PHD finger 2 (in magenta) 
coordinated by Zn4 and Zn5 (Figure S2A). The first PHD finger adopts a mixed α/β fold 
characteristic of canonical PHD fingers, while PHD finger 2 is atypical and is composed 
solely of six α-helical segments with a disordered segment spanning residues 179–188 
(Figure S2A). The Zn knuckle plays a bridging role and forms contacts with both PHD 
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fingers 1 (Figure S2B) and 2 (Figure S2C), resulting in an overall compact fold for the PZP 
motif (Figure S2A).
Structure of AF10PZP Reveals Dynamic Conformational Transition upon H3 Binding
Next, the crystal structure of AF10PZP bound to an H3 peptide was solved. Our attempts at 
crystallization of H3(1-36) peptide bound to AF10PZP were unsuccessful. We therefore 
fused the C-terminus of the AF10 PZP domain (aa 18-208) to the N-terminus of H3(1-36) 
using a (Gly-Ser)6 linker to obtain diffraction quality crystals of the hybrid construct. We 
solved the 2.62 Å crystal structure of the covalently-linked AF10PZP-H3(1-36) peptide 
construct (x-ray statistics in Table 1). The structure of the complex is shown in Figure 2A 
with the protein in a color-coded ribbon representation and the bound peptide in a yellow 
stick representation. A segment of the H3(1-36) peptide spanning residues A21 to K27 is 
bound with directionality (see 2Fo-Fc composite simulated annealing omit map contoured at 
1.2σ in Figure 2B) within a surface channel of the PZP domain (Figure 2C); this minimal 
peptide was sufficient for binding, though with weaker affinity than the longer peptide 
(Figure S1D). Within this channel, intermolecular contacts involving H3 residues T22 
(Figure 2D and S2E), K23 (Figure 2E and S2F), A24 (Figure 2F and S2G), R26 (Figure 2G 
and S2H) and K27 (Figure 2H and S2I) span all sub-domains (PHD finger 1, Zn knuckle and 
PHD finger 2) of the PZP domain. The ε-NH3+ group of unmodified K23 is anchored 
through hydrogen bond formation with the carboxylate group of E179 of the PZP domain 
(Figure 2E). By contrast, the ε-NH3+ group of unmodified K27 is anchored through 
hydrogen bond formation with three backbone carbonyl groups of the PZP domain, leaving 
no room for even mono-methylation at K27 (Figure 2H and S2I).
A segment within PHD finger 2 of AF10PZP, that spans amino acids 179-188, is disordered 
in the 1.60 Å structure in the free state (Figure S2A). Upon complex formation with 
H3(1-36) peptide, this region becomes ordered to form an anti-parallel β-sheet (Figure 2I, 
marked by arrow; free and bound structures superimposition shown in Figure S2D). This 
dynamic β-sheet forms part of the binding channel wall within the PZP domain and 
contributes to the alignment of the bound H3 peptide with residue E179, which emanates 
from this β-sheet platform, directly involved in recognition of the ε-NH3+ group of K23 
(Figure 2E).
Validation of Intermolecular Contacts in Covalently-linked Complex from Site-specific 
Mutation Studies
Alanine substitutions of key amino acids in AF10PZP that interact with H3 largely abolished 
or decreased binding to H3 peptides as determined in pull-down and ITC assays (Figure 3A, 
3B and S1E). These AF10 residues include those that interact with H3T22, H3K23, H3A24, 
H3R26, and H3K27 (Figure 2D–H). In contrast, mutation of residues located on the opposite 
side of the H3-binding surface had no impact on the AF10PZP-H315-34 interaction (Figure 
S1F). In complementary experiments, alanine substitution of two H3 residues contacted by 
AF10PZP, H3R26A and H3K27A, disrupt AF10PZP and AF17PZP binding to rNucs (Figure 
3C). The structure revealed that the bound H3 tail adopts an α-helical conformation, with 
the side chain of H3A25 not making intermolecular contacts with AF10PZP (see Figure 2A). 
H3A25P substitution interrupted α-helix formation and prevented nucleosome binding by 
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AF10PZP and AF17PZP (Figure 3C). Finally, the H3K27M substitution associated with 
pediatric gliomas (Lewis et al., 2013) also disrupted binding (data not shown). Taken 
together, the biochemical, biophysical, and structural data point to a specific interaction 
between AF10PZP and H3 that is exquisitely sensitive to chemical alteration of K27.
It is important to note that the key intermolecular contacts involving H3(22-27) and 
AF10PZP in the crystal structure of the covalently-linked AF10PZP-(Gly-Ser)6-H3(1-36) 
complex have been validated using site-specific mutations of both H3 and AF10PZP residues 
(Figures 3A–C, and S1C-F), ruling out impact on intermolecular recognition resulting from 
the covalent linkage between components of the complex.
The PZP-H3 Interaction Stabilizes AF10 at Chromatin
We next investigated the role of H3-binding by the PZP domain on AF10 function in cells. 
AF10 – as a direct binding partner of DOT1L and regulator of H3K79 methylation – is 
likely chromatin-associated under physiologic conditions. We postulated that the interaction 
between the PZP domain and H3 might therefore regulate AF10 stability at chromatin. To 
test this idea, we established a tetracycline-inducible system in U2OS cells to express GFP-
AF10 and GFP-AF10L107A, a mutant that abolishes H3 binding (Figure 3A, B) and is 
involved in both K23 and K27 side-chain recognition (Figure S2J). Analysis of lysates 
biochemically separated into chromatin-enriched and soluble fractions demonstrated that 
AF10L107A enrichment at chromatin was reduced in comparison to wild-type AF10, with 
more mutant being detected in the soluble fraction (Figure 3D). Decreased chromatin-
association for AF10L107A versus wild-type AF10 was also observed by in situ fractionation 
as an independent method (Figure 3E; see 3F for quantification). Thus, we conclude that 
PZP binding to H3 plays a role in stabilizing AF10 at chromatin in cells.
The AF10-H3 Interaction is Essential for Global H3K79 Dimethylation
We next knocked out AF10 in U2OS cells using the CRISPR/Cas9 system and two 
independent small guide RNAs (sgRNAs) targeting splice sites on the AF10 gene, which 
resulted in loss of AF10 expression and no change in DOT1L expression (Figure S3A and 
S3B). Relative to wild-type cells, knockout of AF10 led to depletion of H3K79me2 levels as 
determined by both Western analysis (Figure 4A) and by mass spectrometry (Figure S3C), 
consistent with previous reports investigating AF10 function and its connection to DOT1L 
catalytic activity (Deshpande et al., 2014; Mohan et al., 2010). Of the three possible methyl 
states at H3K79, the loss of dimethyl was most pronounced, and no changes were detected 
in the methylation levels at several other histone residues (Figures 4A, S3C, and Table S1). 
Similar results were observed when we depleted AF10 in HT1080 cells as a second 
independent cell line (Figure S3D and S3E), whereas depletion of AF17 had no affect on 
H3K79 methylation (Figure S3F), consistent with previous reports (Deshpande et al., 2014; 
Mohan et al., 2010). We note that peptide arrays were employed to test the epitope and 
methyl-state specificity of antibodies used in our studies (data not shown; (Bua et al., 2009; 
Fuchs et al., 2011)). Finally, the levels of monoubiquitination of H2B (H2Bubi), an 
upstream signal that promotes H3K79 methylation (Lee et al., 2007), were unaltered upon 
AF10 depletion (Figure S3G). Taken together, our results are consistent with previous 
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reports that AF10 regulates DOT1L activity and is preferentially required for the generation 
of the dimethyl state at H3K79.
Exogenous AF10 can be expressed in the presence of the AF10-sgRNAs, as the target 
sequences (splice site junctions) are absent from the cDNA. Therefore, to test the functional 
consequences of the AF10-H3 interaction in a cellular context, we established a 
complementation system by knocking out endogenous AF10 in the inducible GFP-AF10 
wild-type and mutant U2OS cell lines. As shown in Figure 4B and S3C, in an AF10 deletion 
background, induction of wild-type GFP-AF10, but not the L107A H3-binding mutant, 
reconstituted H3K79me2 levels to those observed in control cells. In mammals, H3K79 
methylation (both me2 and me3) correlates with gene activity and is thought to promote 
expression, potentially through positive regulation of transcription elongation (McLean et 
al., 2014; Nguyen and Zhang, 2011; Steger et al., 2008). In this context, loss of AF10 led to 
a modest reduction in expression of the DOT1L-target gene PABPC1 (Figure 4C) (Li et al., 
2014; Steger et al., 2008). PABPC1 expression was reconstituted close to control levels 
upon induction of GFP-AF10 but not with GFP-AF10L107A (Figures 4C). At the level of 
chromatin, H3K79me2 is enriched proximal to the transcription start site (TSS) and gene 
body of the PABPC1 gene (Figure 4D). This signal, which is lost in AF10 deleted cells, is 
reconstituted upon induction of GFP-AF10, but not upon induction of GFP-AF10L107A 
(Figure 4D). Consistent with these results, GFP-AF10L107A occupancy at the PABPC1 gene 
was low relative to wild-type GFP-AF10 (Figure 4D), suggesting a model in which the 
inability of the H3-binding mutant to reconstitute H3K79me2 is due to reduced affinity for 
chromatin.
AF10-Mediated H3K79me2 Regulates Expression of Key DOT1L-Target Genes
For most cell types, including U2OS cells, loss of H3K79 methylation due to inhibition of 
DOT1L is well tolerated ((Chen et al., 2013; Deshpande et al., 2013; McLean et al., 2014; 
Nguyen and Zhang, 2011); unpublished observations). In contrast, cell lines derived from 
MLL-fusion leukemias are frequently addicted to DOT1L and inhibitors of DOT1L are 
being developed as chemotherapeutics to treat these difficult cancers (for review see (Daigle 
et al., 2013)). We postulated that the AF10PZP-H3 interaction might be important for a 
subset of MLL-fusion leukemic cells in which the fusion partner lacks chromatin-binding 
activity (see discussion). To test this idea, we established an AF10 complementation system 
in ML2 leukemia cells, a line in which H3K79me2 and H3K27me3 are largely mutually 
exclusive at the protein level as determined by Western analysis and quantitative mass 
spectrometry (Figure S4A and S4B). ML2 cells contain an MLL-AF6 fusion (AF6: ALL1-
Fused gene from chromosome 6, a protein normally involved in cell-cell junctions) and are 
sensitive to DOT1L inhibition (Deshpande et al., 2013)). Like with U2OS and HT1080 cells, 
maintenance of H3K79me2 levels in ML2 cells requires an intact AF10 PZP domain (Figure 
4E, S4C, and S4D). AF10 depletion with loss of H3K79me2 resulted in decreased 
expression in several key DOT1L-target genes, such as HOXA10, and did not affect DOT1L 
protein levels (Figure 4F, S4E, and S4F). The expression of these genes was restored in cells 
complemented with wild-type AF10 but not with AF10L107A (Figure 4F and S4E). Further, 
AF10 depletion in ML2 cells decreased the cellular proliferation rates relative to control 
depleted cells, a phenotype that was reversed upon reconstitution of AF10-depleted ML2 
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cells with wild-type AF10, but not with mutant AF10L107A (Figure 4G). These data argue 
that the PZP-mediated interaction between AF10 and H3 plays a critical role in regulating 
both the expression of DOT1L-target genes and the proliferation of leukemic cells.
DISCUSSION
Here, we identify the PZP domains of AF10 and AF17 as reader domains that have the 
hereto-unknown specificity for H3 in a region spanning K27. In contrast to any previously 
described readers, the AF10 and AF17 PZP-mediated H3-recognition events are specific for 
the unmodified state of H3K27 and obstructed by chemical modification at K27. This 
residue is known to be a highly methylated in embryonic stem cells (Ferrari et al., 2014). In 
the cell lines used in our study, we also we observed a high degree of H3K27 methylation, 
whereas the majority of H3K79 is unmodified, consistent with the notion that H3K79 
modification is repelled by H3K27 methylation (Figure S4G and S4H). Functionally, the 
interaction between the AF10 PZP domain and H3 suggests a molecular mechanism where 
AF10 regulates the stability of DOT1L at chromatin targets, and by extension, the 
generation of H3K79 methylation. Our structural and biochemical analyses have defined the 
key recognition elements that contribute to complex formation. These include the dynamic 
formation of a β-sheet within PHD finger 2 on complex formation that contributes to 
completion of an H3 peptide-binding channel formation (Figure 2 and S2D). In addition, the 
side-chain of unmodified H3K27 is accommodated within a compact, hydrogen bond 
acceptor-lined binding pocket in which even mono-methylation of K27 cannot be tolerated 
due to steric constraints (Figure 1F and S1C).
The exquisite sensitivity of H3-recognition by AF10 to chemical modification at K27 
elucidates a molecular connection between K27 and K79. Indeed, in recent reports focusing 
on either leukemic or somatic cell reprogramming (Bernt et al., 2011; Onder et al., 2012), 
H3K79me2 and H3K27me3 showed a genome-wide anti-correlation in their enrichment 
patterns, consistent with their antagonistic relationship in regulating transcription and our 
proteomic analysis indicating mutual exclusivity of H3K79me2 and H3K27me3 at the 
protein level (Figure S4A and S4B). We propose that H3-recognition by AF10PZP serves to 
ensure the mutual exclusivity of H3K79me2 and H3K27me3 at co-regulated genes by 
directing DOT1L to regions devoid of H3K27 methylation. The crosstalk between these two 
residues also highlights the diversity of functional states and signaling potential associated 
with dynamic modification of H3K27, which includes mono-, di-, tri-methylation, 
acetylation, and the unmodified state. Moreover, our findings suggest a model in which 
H3K27 methylation, in addition to its well-characterized and important role in actively 
directing epigenetic silencing (Vizan et al., 2014), also implicitly promotes silencing by 
repelling AF10 and DOT1L activity from target sites.
In MLL-fusion leukemias, aberrant recruitment of DOT1L to target genes is thought to 
activate a pathologic transcriptional program that promotes leukemogenesis (Deshpande et 
al., 2012; Krivtsov and Armstrong, 2007; McLean et al., 2014; Nguyen and Zhang, 2011; 
Stein and Tallman, 2015). In the majority of cases, the MLL-fusion partner is a DOT1L-
associated protein and directly recruits DOT1L to chromatin. However, for a significant 
number of AML patients with MLL translocations, MLL is not fused to a core DOT1L 
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complex component. In these cases, the mechanism by which DOT1L is targeted to 
chromatin is unclear, yet these cell lines require DOT1L-mediated activation of oncogenic 
genes. We focused on one such fusion (MLL-AF6) and provided evidence that the AF10-H3 
interaction is important for DOT1L functions at chromatin. We postulate that developing 
compounds targeting the binding pocket of AF10PZP for H3 will disrupt H3K79 methylation 
and provide therapeutic value for patients suffering from atypical MLL fusion AMLs, 
potentially in combination with DOT1L inhibitors to mitigate the risk of cancers developing 
resistance. Together, our findings have identified the molecular basis of AF10-dependent 
crosstalk between H3K27 and H3K79, two crucial H3 residues with roles in chromatin 
regulation, epigenetics, and human disease.
EXPERIMENTAL PROCEDURES
AF10PZP, AF17PZP, JADE1PZP, and CBX7 domains were cloned into pGEX-6P-1 for in 
vitro binding experiments. Histone H3 and mutants were cloned into pET3 or pET21a for 
recombinant nucleosome reconstitution. Full length AF10 (NM_004641.3) was originally 
cloned into pENTR3C and then recombined into pCDNA5-Hygro-FRT-TO-GFP-N DEST 
and pLenti CMV Hygro DEST (W117-1) (Addgene). See Supplementary information for 
detailed methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• AF10 PZP domain recognizes unmodified H3K27 to regulate H3K79 
dimethylation
• The PZP domain functions as a single unit to read the modification state at 
H3K27
• PZP-dependent chromatin binding by AF10 regulates DOT1L target genes
• AF10 binding to H3K27 regulates proliferation of MLL-AF6 rearranged 
leukemic cells
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Figure 1. The PZP domains of AF10 and AF17 bind to H3 amino acids 15-34 and the interaction 
is abrogated by H3K27 methylation
(A) Top: Schematic of full length AF10 with the indicated domains. Bottom: Schematic of 
motifs that comprise the PZP domain.
(B) The PZP domains of AF10 and AF17 bind to nucleosomes. Western blot of biotinylated 
recombinant nucleosomes (rNuc) pull-downs incubated with GST, GST-AF10PZP, GST-
AF17PZP and GST-JADE1PZP as indicated.
(C) The N-terminal tail of H3 is necessary for AF10PZP and AF17PZP binding to 
nucleosomes. Pull-down assays as in (B) with nucleosomes containing either wild-type H3 
or H3- N (amino acids 27-135) as indicated. Bottom panel: Western blot showing H3 and 
H3-ΔN used for pull-downs.
(D) Amino acids 15-34 of H3 are sufficient for binding to AF10PZP and AF17PZP. Western 
blot analysis of histone peptide pull-downs with the indicated proteins and biotinylated H3 
peptides.
(E and F) Methylation of H3K27 inhibits binding of AF10PZP and AF17PZP to H3 (aa 
15-34) peptides. (E) Peptide pull-down assays as in (D). (F) ITC was used to determine the 
Kd values for the interaction of AF10PZP with the indicated peptides. Standard deviation was 
derived from nonlinear fitting. See Figure S3A for curves.
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(G) Acetylation of H3K27 inhibits binding of AF10PZP to H3 (aa 15-34) peptides. Pull-
down assays as in (D) with GST-AF10PZP and the indicated biotinylated peptides.
(H) Methylation of H3K27 inhibits binding of AF10PZP and AF17PZP to nucleosomes. 
Nucleosome binding assays as in (B) with the indicated modified rNucs. Bottom three 
panels: Western of H3K4me3, H3k27me3 and total H3 to control for integrity of reagents.
See also Figure S1A–C
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Figure 2. Structural basis of H3 recognition by AF10PZP
(A) 2.6 Å crystal structure of AF10PZP (18-208) complexed with H3(1-36) peptide.
(B) Fo-Fc omit map (2.5σ level) of the bound H3 peptide (side chain density can be traced 
from A21 to K27) in the structure of AF10PZP-H3 complex.
(C) Positioning of the bound H3 peptide (A21 to K27 in stick representation) within the 
AF10PZP binding site (electrostatic surface representation).
(D–H) Details of intermolecular contacts involving residues T22 (panel D), K23 (panel E), 
A24 (panel F), R26 (panel G) and K27 (panel H) of the bound H3 peptide with the AF10PZP 
in the structure of the complex.
(I) Formation of an anti-parallel β-sheet within the PHD2 finger of AF10PZP upon complex 
formation with H3(1-36) peptide.
See also Figures S1D and S2
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Figure 3. Structure-guided mutations disrupt AF10PZP binding to H3 in vitro in cells
(A and B) Structure-guided mutations in AF10PZP disrupt binding to H3(15-34) peptides. 
(A) Peptide pull-down assays with the indicated mutants and peptides. (B) ITC as in Figure 
1F with the AF10PZP derivatives as in (A) binding to H3(15-34) peptide. Standard deviation 
was derived from nonlinear fitting. See Figure S3C for curves.
(C) Mutations of key residues on H3 disrupt AF10PZP-binding to nucleosomes. Pull-down 
assays as in Figure 1B with nucleosomes containing either wild-type H3 or H3 with the 
indicated point mutations. Bottom panel: Western blot showing H3 as a loading control.
(D–F) The AF10PZP-H3 interaction stabilizes AF10 at chromatin. (D) Western blot analysis 
with indicated antibodies of lysates biochemically separated into soluble and chromatin-
enriched (Chrom) fractions from U2OS cells expressing wild-type or mutant GFP-AF10. 
WCE: whole cell extract is shown to control for total AF10 expression. Tubulin and H3 
levels are shown as control for the integrity of fractionation. (E) In situ fractionation of 
HeLa cells expressing GFP-AF10 or GFP-AF10L107A. Representative image of GFP 
localization determined in the indicated cell lines ± detergent treatment prior to fixation and 
visualization by fluorescence microscopy. DAPI is shown to indicate nuclei of cells. (F) 
Quantification of in situ fractionation experiments as in (E). Normalized fluorescence refers 
to the average intensity of signal in the absence of detergent treatment (see methods). Error 
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bars represent the standard error of the mean (SEM) based on counting 30–60 cells from 
three independent fields and two biological replica.
See also Figures S1E–F and S2J
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Figure 4. An intact AF10 PZP domain is required for DOT1L enzymatic and cellular functions 
in leukemic cells
(A) Depletion of AF10 using the CRISPR/Cas9 system specifically decreases global 
H3K79me2 level in U2OS cells. Western analysis with the indicated antibodies of whole 
cell extract (WCE) stably expressing control sgRNA or two independent sgRNAs targeting 
AF10. H3 is shown as a loading control.
(B) AF10PZP-binding to H3 is required for global H3K79me2. Western analysis as in (A) 
with cell lines expressing either control or AF10-targeting sgRNA. Dox: cells were treated 
with doxycycline to induce expression of GFP, GFP-AF10, and GFP-AF10L107A as shown.
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(C) AF10PZP-binding to H3 regulates expression of DOT1L-target gene PABPC1. 
Quantitative real-time PCR (qPCR) analysis of PABPC1 mRNA expression level in the 
indicated cell lines. Error bars indicate SEM from three experiments.
(D) An intact AF10PZP domain promotes H3K79me2 enrichment at the PABPC1 gene. Top 
panel: schematic of PABPC1 gene with the position of the two primers used for direct 
chromatin immunoprecipitation (ChIP) assays indicated. Middle panel: Key showing the cell 
lines used for the ChIP assays. Left bottom panel: H3K79me2 enrichment at PABPC1 with 
the H3K79me2 signal normalized to total H3 signal. Right bottom panel: GFP enrichment at 
PABPC1 shown as % GFP signal/input. Error bars indicate the SEM from three 
experiments.
(E) The AF10-H3 interaction regulates H3K79me2 in ML2 leukemia cells. Western analysis 
as in (A) in ML2 cells treated as indicated.
(F) AF10 binding to H3 required for full expression of DOT1L-target genes in ML2 
leukemia cells. Analysis of HOXA10 and RUNX1 mRNA expression as in (C) in ML2 cells 
treated as indicated in the key. Error bars represent the SEM from three experiments.
(G) AF10PZP-binding to H3 is required for ML2 leukemia cells to maintain normal 
proliferative rate. Growth curve of cell lines treated as indicated in the key. Error bars 
represent the SEM from three independent experiments.
See also Figures S3 and S4
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Table 1
Data collection and refinement statistics.
AF10 (1-208) AF10 (18-208)-(GS)6-H3(1-36)
Data collection
Space group P 41 21 2 P 21
Cell dimensions
 a, b, c (Å) 51.9, 51.9, 147.9 42.9, 80, 59.3
 a, b, g () 90, 90, 90 90, 102.1, 90
Resolution (Å) 50 - 1.6 (1.63 - 1.60) 50 - 2.62 (2.76 -2.62)
Wavelength (Å) 1.283 0.979
Rsym or Rmerge 0.075 (0.683) 0.148 (0.545)
I/sI 55.0 (2.56) 10.7 (2.56)
Completeness (%) 99.8 (99.3) 98.1 (99.2)
Redundancy 7.9 (4.6) 3.1 (3.1)
Refinement
Resolution (Å) 50 - 1.6 (1.63 - 1.60) 50 - 2.62 (2.76 - 2.62)
No. reflections 50458 (3652) 11659 (1167)
Rwork/Rfree 0.19/0.21 0.18/0.24
No. atoms 1432 2857
 Protein 1319 2784
 Zn 5 10
 Water 108 63
Wilson B 21.97 24.93
B-factors 29.68 29.33
 Protein 29.33 29.26
 Zn 23.56 22.15
 Water 34.25 24.11
Ramachandran outliers 0 0
Ramachandran allowed 1.2 % 3.3 %
Ramachandran favored 98.8 % 96.7 %
R.m.s deviations
 Bond lengths (Å) 0.007 0.004
 Bond angles (°) 1.001 0.805
*
Highest resolution shell is shown in parenthesis.
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